Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Byetta Safety Concerns Could Set Roadblocks Ahead For New GLP-1s

This article was originally published in The Pink Sheet Daily

Executive Summary

Amylin/Lilly’s Byetta LAR and Novo Nordisk’s liraglutide could face tougher regulatory scrutiny after cases of pancreatitis are linked to exenatide.

You may also be interested in...



Medco Study Lets Januvia And Byetta Off The Hook For Pancreatitis

Pharmaceutical benefits manager's review of almost 800,000 claims does not show higher risk for these two drugs, despite label warnings.

Medco Study Lets Januvia And Byetta Off The Hook For Pancreatitis

Pharmaceutical benefits manager's review of almost 800,000 claims does not show higher risk for these two drugs, despite label warnings.

Amylin Submits Once-Weekly Byetta After Shedding 200 Sales Reps

Label with expanded language about thyroid cancer risk is expected.

Related Content

Topics

UsernamePublicRestriction

Register

ID1130765

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel